For the quarter ending 2026-03-31, RXST had -$2,376K decrease in cash & cash equivalents over the period. -$11,650K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -15,884 | -9,152 | -9,816 | -19,976 |
| Depreciation and amortization | 834 | 851 | 854 | 1,561 |
| Provision for bad debts | 0 | 0 | 0 | 32 |
| Amortization of debt issuance costs and premium | - | 0 | - | - |
| Loss on extinguishment of debt | - | 0 | - | - |
| Amortization of right-of-use lease assets | 0 | - | 0 | 0 |
| Amortization of discount on short-term investments | 1,854 | 1,832 | 2,144 | 4,541 |
| Stock-based compensation | 7,945 | 7,817 | 8,108 | 15,687 |
| Provision for excess and obsolete inventory | 60 | 616 | 66 | 1,250 |
| Accounts receivable | -936 | -788 | -3,907 | -1,960 |
| Inventories | 3,370 | 3,225 | 3,955 | 4,302 |
| Prepaid and other assets | -120 | 881 | -322 | -1,742 |
| Accounts payable | 1,577 | 2,204 | -86 | -1,491 |
| Accrued expenses and other liabilities | -1,255 | 1,698 | 1,557 | -5,130 |
| Net cash used in operating activities | -10,891 | -1,116 | -1,187 | -13,208 |
| Purchases of property and equipment | 759 | 1,137 | 581 | 2,112 |
| Maturities of short-term investments | 110,000 | 90,000 | 60,000 | 110,000 |
| Purchases of short-term investments | 100,393 | 98,477 | 68,423 | 72,381 |
| Net cash used in investing activities | 8,848 | -9,614 | -9,004 | 35,507 |
| Proceeds from term loan | - | 0 | - | - |
| Repayment of term loan | - | 0 | - | - |
| Proceeds from issuance of common stock from public offering | - | 0 | 0 | 0 |
| Payments of deferred offering costs | - | 0 | 0 | 0 |
| Proceeds from issuance of common stock | 144 | 1,056 | 131 | 2,764 |
| Payments of debt issuance costs | - | 0 | - | 0 |
| Payments for employee taxes related to stock compensation | -473 | -2 | -642 | -1,418 |
| Principal payments on finance lease liabilities | 7 | -9 | 19 | 16 |
| Net cash (used in) provided by financing activities | -336 | 1,063 | -530 | 1,330 |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | 3 | -15 | -2 | 20 |
| Net increase in cash, cash equivalents and restricted cash | -2,376 | -9,683 | -10,723 | 23,649 |
| Cash, cash equivalents and restricted cash - beginning of period | 20,699 | 30,382 | 17,456 | - |
| Cash, cash equivalents and restricted cash - end of period | 18,323 | 20,699 | 30,382 | - |
RxSight, Inc. (RXST)
RxSight, Inc. (RXST)